Secreted PCSK9 downregulates low density lipoprotein receptor through receptor-mediated endocytosis. - Wikidata - wikimedia - TriplyDB

Secreted PCSK9 downregulates low density lipoprotein receptor through receptor-mediated endocytosis.

Secreted PCSK9 downregulates low density lipoprotein receptor through receptor-mediated endocytosis.

http://www.wikidata.org/entity/Q40142846

about

Self-association of human PCSK9 correlates with its LDLR-degrading activity Hepatocyte nuclear factor 1alpha plays a critical role in PCSK9 gene transcription and regulation by the natural hypocholesterolemic compound berberine New developments in atherosclerosis: clinical potential of PCSK9 inhibition Proprotein convertase subtilisin/kexin type 9: from the discovery to the development of new therapies for cardiovascular diseases Evaluation of the effect of genetic variation on the relationship between statins, cardiovascular disease and cancer Antagonism of Secreted PCSK9 Increases Low Density Lipoprotein Receptor Expression in HepG2 Cells A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates PCSK9 regulates neuronal apoptosis by adjusting ApoER2 levels and signaling IDOL stimulates clathrin-independent endocytosis and multivesicular body-mediated lysosomal degradation of the low-density lipoprotein receptor.Fenofibrate treatment increases human serum proprotein convertase subtilisin kexin type 9 levels.Efficacy and safety of proprotein convertase subtilisin/kexin type 9 monoclonal antibody in adults with familial hypercholesterolemia Proprotein convertase subtilisin kexin type 9 promotes intestinal overproduction of triglyceride-rich apolipoprotein B lipoproteins through both low-density lipoprotein receptor-dependent and -independent mechanisms.High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol Inhibition of PCSK9 transcription by berberine involves down-regulation of hepatic HNF1α protein expression through the ubiquitin-proteasome degradation pathway Molecular and cellular function of the proprotein convertase subtilisin/kexin type 9 (PCSK9).A cholesterol-lowering VLP vaccine that targets PCSK9 Strong induction of PCSK9 gene expression through HNF1alpha and SREBP2: mechanism for the resistance to LDL-cholesterol lowering effect of statins in dyslipidemic hamsters Effects of currently prescribed LDL-C-lowering drugs on PCSK9 and implications for the next generation of LDL-C-lowering agents.Effects of elaidic acid on lipid metabolism in HepG2 cells, investigated by an integrated approach of lipidomics, transcriptomics and proteomics.Reduction of circulating PCSK9 and LDL-C levels by liver-specific knockdown of HNF1α in normolipidemic mice.Blockade of cholesterol absorption by ezetimibe reveals a complex homeostatic network in enterocytes Hepatocytes respond differently to major dietary trans fatty acid isomers, elaidic acid and trans-vaccenic acid.Common and rare gene variants affecting plasma LDL cholesterol Plasma PCSK9 levels are significantly modified by statins and fibrates in humans PCSK9 is required for the disposal of non-acetylated intermediates of the nascent membrane protein BACE1.Differential effects of PCSK9 loss of function variants on serum lipid and PCSK9 levels in Caucasian and African Canadian populations.Inflammation stimulates the expression of PCSK9 Decreased APOE-containing HDL subfractions and cholesterol efflux capacity of serum in mice lacking Pcsk9.PCSK9: a convertase that coordinates LDL catabolism.Function and distribution of circulating human PCSK9 expressed extrahepatically in transgenic mice Lysine acetylation in the lumen of the ER: a novel and essential function under the control of the UPR.Potential of proprotein convertase subtilisin/kexin type 9 based therapeutics.Low-density lipoprotein lowering in 2013 by nonstatin agents: the discovery and development of promising novel targeted therapies.Landmark lipid-lowering trials in the primary prevention of cardiovascular disease.Current Phase II proprotein convertase subtilisin/kexin 9 inhibitor therapies for dyslipidemia.Novel treatments for familial hypercholesterolemia: pharmacogenetics at work.The role of antisense oligonucleotide therapy in patients with familial hypercholesterolemia: risks, benefits, and management recommendations.Oxidized low-density lipoprotein as a biomarker of cardiovascular diseases.The novel function of HINFP as a co-activator in sterol-regulated transcription of PCSK9 in HepG2 cells.PCSK9 inhibition: current concepts and lessons from human genetics.

P2860

Q24306591-01C5C3BD-36E9-4EAE-B3EE-D2A6454947B8 Q24652495-5987328B-E5A3-499C-B848-75F47862EDBE Q26783407-F355DA20-A3AB-4134-9432-2141568FEB95 Q27009477-80BFD4B0-2F15-4D6C-A7DD-866B9F024D38 Q27026358-D333B95C-8544-4812-9EC4-C0030239AC06 Q27653836-0BAF779D-AFA1-40C5-B1B4-96F338D1B3F1 Q27655476-02C9AF22-D4AA-4CCA-8FA9-C7EA36D61E1B Q28586625-35981188-679E-46C4-9917-E48815249130 Q30538763-20123A21-D1E9-457A-88F6-C13E5228E639 Q33577851-AD9F7DDD-FC7A-4AD1-8C94-179B6CC580CF Q33728343-A3029ABF-240E-4D70-88CF-44160A6A7BEF Q33970677-6FBEFA48-6464-49B8-BB6E-443695F32BFB Q34053143-9937669B-8B95-4A92-990E-36C8E324D182 Q34455663-99F7489E-043C-492A-9680-E38BDF5512D3 Q34458693-3FE1B637-BFFB-447F-BBD1-C0A0AE9F0B46 Q34496015-03396D85-BC49-435B-ADB1-DBA1C212CEBA Q34559944-FEC75F56-CF29-4532-8CD7-ABEB77E49385 Q34662589-559F3DFB-8270-4524-9523-763A4F5B86A6 Q34994595-7F4FEFB0-10B4-4B37-A5F6-E34362DE76DA Q35217031-6EC8F9D1-1466-4D70-88F4-94334B9B6AEE Q36020286-DE5DE552-5264-4C05-9D52-0F33634FABC2 Q36336243-F1FEB907-14DB-4858-BAD6-05BA80FF79A7 Q36711327-500BD0CA-AFA9-4E2C-90EF-EF51A3170123 Q36728777-56CD7AC3-61C6-4517-AFEA-B97FF1FFFEC7 Q36862604-FB852095-6F24-483D-AFCB-F62F9B6E4458 Q36866980-AB417085-35D3-4D7B-859C-9F24AC94D3F7 Q36945328-E3A21D3B-C1EC-4165-9162-34A4D93AF241 Q37116362-6EEC739C-FCCC-409A-AA48-4599503BB220 Q37173223-28F4892C-B726-452A-85B3-CCA276ADA4B8 Q37297854-057BF504-8938-42A9-A44B-FBD42F6C0E4B Q38068055-BE44207D-6A58-4101-9F75-BFE4423F1DA4 Q38078264-E01E6559-64A8-4687-B3F5-3A6CCBDFDB55 Q38098501-38A9F6D4-D6EF-4AD3-8A8A-EDAD809AE878 Q38110701-6FEE33E3-19AB-40DB-8488-60A286219542 Q38124404-9D81BC12-227F-4790-8248-4797E7A90330 Q38217797-9BE10A84-1C1F-4B69-A456-FEE0636AA0F6 Q38268342-26EB6921-DC37-4FA4-9E6B-701249539BC6 Q38299279-1431359B-36D1-477A-842F-435E2B95139C Q38328173-AF7AF348-CE0F-4736-996A-5CD03009DF08 Q38338236-35F08DF6-B7AB-4650-A73D-158FF990FBBC

P2860

Secreted PCSK9 downregulates low density lipoprotein receptor through receptor-mediated endocytosis.

http://www.wikidata.org/entity/Q40142846

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

2007年论文

@zh

2007年论文

@zh-cn

name

Secreted PCSK9 downregulates l ...... receptor-mediated endocytosis.

@en

type

label

Secreted PCSK9 downregulates l ...... receptor-mediated endocytosis.

@en

prefLabel

Secreted PCSK9 downregulates l ...... receptor-mediated endocytosis.

@en

P1433

Q40142846-D73E3711-055A-4482-B630-66561C5C40CE

P1476

Q40142846-568C3541-31A2-4BBB-963F-EEBD86F5B08D

P2093

Q40142846-09059E6E-79C5-415F-8C12-461FEE4DB3A5

Q40142846-0954FA33-8573-4847-A69F-4FE1E00CD9B2

Q40142846-303923A6-2341-4530-B450-5A6A32B23E21

Q40142846-359B6E11-DA0D-42A5-B018-B5CF229F8CAE

Q40142846-49D1695D-BD35-44E9-B0A9-CC74DF24299E

Q40142846-677C2401-1F24-4DC1-BC78-F308A915B893

Q40142846-78371AAD-16D3-419F-8881-0B732873E2C5

Q40142846-876A4496-68FC-404C-9539-FB24358A0475

Q40142846-B62F8520-A087-4C9E-B4AF-5735A0028DB6

Q40142846-B92F6AFF-E763-49AC-AF2F-08557A6FC458

P2860

Q40142846-06C25321-7F51-4937-BF0D-D98F4584837C

Q40142846-1685A652-69F0-41A3-A71B-6A06F92F264C

Q40142846-1C33D5FE-708A-4BED-81C0-DB45EE08972A

Q40142846-1D5ED837-3F39-488D-85A8-4A6A2EBCC7BB

Q40142846-1E60B1B3-9F02-4653-B90A-F33EE86B2B73

Q40142846-1ECC63D7-272C-4280-8A40-489B8D1D6355

Q40142846-22E39685-57D5-4C43-8BB4-B62B610DF215

Q40142846-2733D158-F851-45B9-A3E2-0306333710C3

Q40142846-34A4DB67-91AE-46CE-8C8B-34C976DA1C48

Q40142846-36C1A1DB-1137-4A7F-88EB-3294E81E40F9

P304

Q40142846-96F64C98-817A-4FA5-AF97-C9F978FB888B

P31

Q40142846-F12E52DE-4E5E-4B20-A6BF-AC2EB911DA64

P356

Q40142846-AAE34489-304F-45A5-8B28-BD6F7EFAB3E2

P433

Q40142846-A7FD8FD1-2B62-4321-A13D-59D0784AFB0A

P478

Q40142846-3A4625CD-BF3A-42E2-A9B9-BB75E8D00686

P577

Q40142846-F7A77483-5EDA-41CF-B7AF-04D053E621AC

P698

Q40142846-5D10D4D0-81D1-454B-B288-95A4F9AAFC77

P921

Q40142846-7059C8E4-9E52-4F93-805C-2C4B31BBFD55

P356

JLR.M700071-JLR200

P1433

Journal of Lipid Research

P1476

Secreted PCSK9 downregulates l ...... receptor-mediated endocytosis.

@en

P2093

Aimin Lin

http://www.w3.org/2001/XMLSchema#string

David E Moller

http://www.w3.org/2001/XMLSchema#string

Deshun Lu

http://www.w3.org/2001/XMLSchema#string

Guoqing Cao

http://www.w3.org/2001/XMLSchema#string

He Wang

http://www.w3.org/2001/XMLSchema#string

Mariam E Ehsani

http://www.w3.org/2001/XMLSchema#string

Patrick I Eacho

http://www.w3.org/2001/XMLSchema#string

Robert J Konrad

http://www.w3.org/2001/XMLSchema#string

Robert J Schmidt

http://www.w3.org/2001/XMLSchema#string

Shaoyou Chu

http://www.w3.org/2001/XMLSchema#string

P2860

Molecular identification of the sterol-regulated luminal protease that cleaves SREBPs and controls lipid composition of animal cells

The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation

Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice

Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype

A proteolytic pathway that controls the cholesterol content of membranes, cells, and blood

Mutations in PCSK9 cause autosomal dominant hypercholesterolemia

Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9

A receptor-mediated pathway for cholesterol homeostasis

Sequence variations in PCSK9, low LDL, and protection against coronary heart disease

Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment.

P304

1488-1498

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1194/JLR.M700071-JLR200

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

48

http://www.w3.org/2001/XMLSchema#string

P577

2007-04-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17449864

http://www.w3.org/2001/XMLSchema#string

P921